Eli Lilly, MiNA Therapeutics Partner to Develop saRNA Therapies

Eli Lilly has partnered with UK-based MiNA Therapeutics to develop treatments using small- activating RNA (saRNA) technology, a new class of drugs pioneered by MiNA.

Also known as oligonucleotides, short DNA or RNA molecules, saRNAs have shown potential for treating a range of diseases by activating genes to restore normal function to compromised cells.

Under the agreement, MiNA will use its saRNA platform to investigate up to five potential treatments chosen by Lilly, which will lead clinical development and commercialization.

MiNA will receive an initial payment of $25 million upfront and is eligible to receive up to $245 million per target, as well as royalties on sales.